Relationship between GSTP1 Ile 105Val polymorphism and docetaxel-induced peripheral neuropathy: Clinical evidence of a role of oxidative stress in taxane toxicity

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 736-740

  Mir, Olivier ^a   Alexandre, J ^a   Tran, A ^a   Durand, J P ^a   Pons, G ^a   Treluyer, J M ^a   Goldwasser, F ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Docetaxel; GST; Oxidative stress; Peripheral neuropathy; Pharmacogenetics; Polymorphism

Indexed keywords

ALANINE; DOCETAXEL; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; LEUCINE; TAXANE DERIVATIVE; VALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 63549083114     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn698     Document Type: Article

References (32)

1. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46.
2. Alexandre J, Bleuzen P, Bonneterre J et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000; 18: 562-573.
3. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003; 21: 3016-3024.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
5. Hilkens PH, Verweij J, Stoter G et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-108.
6. Hilkens PH, Verweij J, Vecht CJ et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8: 187-190.
7. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-1642.
8. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
9. Cao D, Qiao B, Ge Z, Yuan Y. Amplification loop cascade for increasing caspase activity induced by docetaxel. J Cell Biochem 2005; 96: 810-820.
10. Alexandre J, Batteux F, Nicco C et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 2006; 119: 41-48.
11. Alexandre J, Nicco C, Chereau C et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006; 98: 236-244.
12. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene 2006; 25: 1639-1648.
13. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
14. Park JS, Yamamoto W, Sekikawa T et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 2002; 20: 333-338.
15. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-431.
16. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-166.
17. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-580.
18. Alexandre J, Rey E, Girre V et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: A prospective study. Ann Oncol 2007; 18: 168-172.
19. Ambrosone CB, Sweeney C, Coles BF et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61: 7130-7135.
20. Harries LW, Stubbins MJ, Forman D et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-644.
21. Wang Y, Spitz MR, Schabath MB et al. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: A case-control study. Lung Cancer 2003; 40: 25-32.
22. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK signalling by GSTp. EMBO 1999; 18: 1321-1334.
23. Henderson CJ, McLaren AW, Moffat GJ et al. Pi-Class glutathione S-transferase: Regulation and function. Chem Biol Interact 1998; 111-2: 69-82.
24. Elsby R, Kitteringham NR, Goldring CE et al. Increased constitutive c-Jun N-terminal kinase signalling in mice lacking glutathione S-transferase Pi. J Biol Chem 2003; 278: 22243-22249.
25. Henderson CJ, Wolf CR, Kitteringham N et al. Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci USA 2000; 97: 12741-12745.
26. Persohn E, Canta A, Schoepfer S et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005; 41: 1460-1466.
27. Lecomte T, Landi B, Beaune P et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050-3056.
28. Zimniak P, Nanduri B, Pikula S et al. Naturally occurring human glutathione Stransferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994; 224: 893-899.
29. Watson MA, Stewart RK, Smith GB et al. Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280.
30. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene conferdifferential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002; 12: 543-553.
31. Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42: 2893-2896.
32. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483.